“Petite” p value: A Researchers’ Dream! Readers, Beware of the Pit …
Sharada Mailankody
Keywords :
Misuse, p value, Pitfalls, Statistics
Citation Information :
Mailankody S. “Petite” p value: A Researchers’ Dream! Readers, Beware of the Pit …. Indian J Crit Care Med 2020; 24 (S3):140-141.
“What is the magic word for publication?” “The p value <0.05%” seems like an automatic answer from the researchers. Is that right? Let us take a quick peek at this seemingly simple gate-pass to publications!
Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philos Mag 1900;50(302):157–175. DOI: 10.1080/14786440009463897.
Wasserstein RL, Lazar NA. The ASA's statement on p-values: context, process, and purpose. Am Stat 2016;70(2):129–133. DOI: 10.1080/00031305.2016.1154108.
Nahm FS. What the p values really tell us. Korean J Pain 2017;30(4):241–242. DOI: 10.3344/kjp.2017.30.4.241.
Ioannidis JPA. The proposal to lower P value thresholds to .005. JAMA 2018;319(14):1429–1430. DOI: 10.1001/jama.2018.1536.
Chavalarias D, Wallach JD, Li AH, Ioannidis JP. Evolution of reporting P values in the biomedical literature, 1990-2015. JAMA 2016;315(11):1141–1148. DOI: 10.1001/jama.2016.1952.
Fanelli D. Negative results are disappearing from most disciplines and countries. Scientometrics 2011;90(3):891–904. DOI: 10.1007/s11192-011-0494-7.
Nead KT, Wehner MR, Mitra N. The use of “Trend” statements to describe statistically nonsignificant results in the oncology literature. JAMA Oncol 2018;4(12):1778–1779. DOI: 10.1001/jamaoncol.2018.4524.
JAMA Oncology, JAMA Network. Instructions for authors. Available at https://jamanetwork.com/journals/jamaoncology/pages/instructions-for-authors. Last accessed on 16 March 2020.
Adamina M, Tomlinson G, Guller U. Bayesian statistics in oncology. Cancer 2009;115(23):5371–5381. DOI: 10.1002/cncr.24628.
Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a fragility index. J Clin Epidemiol 2014;67(6):622–628. DOI: 10.1016/j.jclinepi.2013.10.019.
Del Paggio JC, Tannock IF. The fragility of phase 3 trials supporting FDA-approved anticancer medicine: a retrospective analysis. Lancet Oncol 2019;20(8):1065–1069. DOI: 10.1016/S1470-2045(19)30338-9.
Ventola CL. Mobile devices and apps for health care professionals: uses and benefits. P T 2014;39(5):356–364.
Isaac T, Zheng J, Jha A. Use of UpToDate and outcomes in US hospitals. J Hosp Med 2012;2(2):85–90. DOI: 10.1002/jhm.944.
